Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This combination therapy, developed by Universitas Diponegoro, pairs the dual 5-alpha-reductase inhibitor dutasteride with Aloe Vera extract for the treatment of benign prostatic hyperplasia (BPH). Dutasteride works by inhibiting both Type I and Type II isoforms of the 5-alpha-reductase enzyme, which prevents the conversion of testosterone into dihydrotestosterone (DHT), the primary androgen driving prostate growth. The addition of Aloe Vera extract is intended to target angiogenesis pathways, specifically by reducing vascular endothelial growth factor (VEGF) levels, potentially offering a synergistic effect on prostate volume reduction and improvement in urinary flow (uroflowmetry) compared to standard monotherapy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on aloe vera + dutasteride.